The drug targets a gene mutation that's present in about half of melanomas, the deadliest form of skin cancer. "Zelboraf is a huge step forward in the fight against metastatic melanoma and the advancement of treatment for the deadliest form of skin cancer," Dr. Anna Pavlick, director of the NYU Melanoma Program at the NYU Cancer Institute, New York City, said in a university statement. She took part in phase II and III trials of the drug and is an advisor to Zelboraf's maker, Genentech. "The approval of Zelboraf will make a significant impact on the survival and outcomes of advanced melanoma patients," Pavlick added. "Patients taking the drug Zelboraf were 63 percent less likely to die from advanced melanoma than patients given standard chemotherapy alone," she noted.The drug should be available within weeks. The side effects listed in the above-linked article appear to be rather significant.
Wednesday, August 17, 2011
FDA Approves Melanoma Drug
The FDA today approved a first-of-its-kind medication to treat melanoma.